List of patient-reported quality of life surveys: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
No edit summary
No edit summary
Line 21: Line 21:
| accessdate = 09/10/2013 }}</ref><ref>{{cite journal|last=Cascione|first=Mark|coauthors=Wynn, Daniel; Agashivala, Neetu; McCague, Kevin; Pestreich, Linda; Schofield, Lesley; Kim, Edward; Barbato, Luigi|title=Patient-Reported Treatment Satisfaction, Reasons for Therapy Change, and Health-Related Quality of Life at Baseline from the Trial To Evaluate Patient OutComes, Safety and Tolerability of Fingolimod|journal=Neurology|date=12/02/2013|volume=80|issue=1|url=http://www.neurology.org/cgi/content/meeting_abstract/80/1_MeetingAbstracts/P03.222|accessdate=9 October 2013}}</ref> and [[rivastigmine]].<ref>{{cite journal|last=Maurer|first=M|coauthors=Ortler, S; Baier, M; Meergans, M; Scherer, P; Hofmann, WE; Tracik, F.|title=Randomised multicentre trial on safety and efficacy of rivastigmine in cognitively impaired multiple sclerosis patients|journal=Multiple Sclerosis|date=15/10/2012|volume=19|issue=5|pages=631-638|doi=10.1177/1352458512463481|url=http://msj.sagepub.com/content/19/5/631.abstract|accessdate=9 October 2013}}</ref> and has been translated into ten different languages.
| accessdate = 09/10/2013 }}</ref><ref>{{cite journal|last=Cascione|first=Mark|coauthors=Wynn, Daniel; Agashivala, Neetu; McCague, Kevin; Pestreich, Linda; Schofield, Lesley; Kim, Edward; Barbato, Luigi|title=Patient-Reported Treatment Satisfaction, Reasons for Therapy Change, and Health-Related Quality of Life at Baseline from the Trial To Evaluate Patient OutComes, Safety and Tolerability of Fingolimod|journal=Neurology|date=12/02/2013|volume=80|issue=1|url=http://www.neurology.org/cgi/content/meeting_abstract/80/1_MeetingAbstracts/P03.222|accessdate=9 October 2013}}</ref> and [[rivastigmine]].<ref>{{cite journal|last=Maurer|first=M|coauthors=Ortler, S; Baier, M; Meergans, M; Scherer, P; Hofmann, WE; Tracik, F.|title=Randomised multicentre trial on safety and efficacy of rivastigmine in cognitively impaired multiple sclerosis patients|journal=Multiple Sclerosis|date=15/10/2012|volume=19|issue=5|pages=631-638|doi=10.1177/1352458512463481|url=http://msj.sagepub.com/content/19/5/631.abstract|accessdate=9 October 2013}}</ref> and has been translated into ten different languages.
* '''[[Rheumatoid Arthritis]].'''The Rheumatoid Arthritis Quality of Life (RAQoL) questionnaire determines the effect [[rheumatoid arthritis]] has on a patient’s [[quality of life]]<ref>{{cite journal|last=de Jong|first=Z.|coauthors=van der Heijde, D.; McKenna, S.P.; Whalley, D.|title=The reliability and construct validity of the RAQoL: a rheumatoid arthritis-specific quality of life instrument.|journal=Rheumatology|date=1997|volume=36|issue=8|pages=878-883|doi=10.1093/rheumatology/36.8.878|url=http://rheumatology.oxfordjournals.org/content/36/8/878.abstract|accessdate=30 September 2013}}</ref>. The RAQoL has 30 items with a yes and no response format<ref>{{cite journal|last=Adams|first=Jo|coauthors=Chapman, Judith; Bradley, Sarah; Ryan, Sarah Jane|title=Literacy levels required to complete routinely used patient-reported outcome measures in rheumatology|journal=Rheumatology|date=2013|volume=52|issue=3|pages=460-464|doi=10.1093/rheumatology/kes296|url=http://rheumatology.oxfordjournals.org/content/52/3/460.abstract|accessdate=30 September 2013}}</ref> and takes about six minutes to complete<ref>{{cite journal|last=de Jong|first=Z.|coauthors=van der Heijde, D.; McKenna, S.P.; Whalley, D.|title=The reliability and construct validity of the RAQoL: a rheumatoid arthritis-specific quality of life instrument.|journal=Rheumatology|date=1997|volume=36|issue=8|pages=878-883|doi=10.1093/rheumatology/36.8.878|url=http://rheumatology.oxfordjournals.org/content/36/8/878.abstract|accessdate=30 September 2013}}</ref>. The RAQoL has been used in [[clinical studies]] in order to confirm the efficacy of [[tocilizumab]]<ref>{{cite journal|last=Dougados|first=Maxime|coauthors=Kissel, Karsten; Sheeran, Tom; Tak, Paul P.; Conaghan, Philip G.; Mola, Emilio Martin; Schett, Georg; Amital, Howard; Navarro-Sarabia, Federico; Hou, Antony; Bernasconi, Corrado; Huizinga, TWJ|title=Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)|journal=Annals of Rheumatic Disease|date=2013|volume=72|issue=1|pages=43-50|doi=10.1136/annrheumdis-2011-201282|url=http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3551223/|accessdate=2 October 2013}}</ref><ref>{{cite web|title=Efficacy of tocilizumab in patients with rheumatoid arthritis|url=http://www.controlled-trials.com/ISRCTN21216199|work=Current Controlled Trials|publisher=Springer Science+Business Media.|accessdate=2 October 2013}}</ref> and [[infliximab]]<ref>{{cite journal|last=Quinn|first=Mark A.|coauthors=Conaghan, Philip G.; O'Connor, Philip J.; Karim, Zunaid; Greenstein, Adam; Brown, Andrew; Brown, Clare; Fraser, Alexander; Jarret, Stephen; Emery, Paul|title=Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twelve-month randomized, double-blind, placebo-controlled trial|journal=Arthritis & Rheumatism|date=07/01/2005|volume=52|issue=1|pages=27-35|doi=10.1002/art.20712|url=http://onlinelibrary.wiley.com/doi/10.1002/art.20712/abstract|accessdate=2 October 2013}}</ref><ref>{{cite journal|last=Bejarano|first=Victoria|coauthors=Conaghan, Philip G.; Quinn, Mark A.; Saleem, Benazir; Emery, Paul|title=Benefits 8 years after a remission induction regime with an infliximab and methotrexate combination in early rheumatoid arthritis.|journal=Rheumatology|date=2010|volume=49|issue=10|pages=1971-1974|doi=10.1093/rheumatology/keq194|url=http://rheumatology.oxfordjournals.org/content/49/10/1971.long|accessdate=2 October 2013}}</ref>.
* '''[[Rheumatoid Arthritis]].'''The Rheumatoid Arthritis Quality of Life (RAQoL) questionnaire determines the effect [[rheumatoid arthritis]] has on a patient’s [[quality of life]]<ref>{{cite journal|last=de Jong|first=Z.|coauthors=van der Heijde, D.; McKenna, S.P.; Whalley, D.|title=The reliability and construct validity of the RAQoL: a rheumatoid arthritis-specific quality of life instrument.|journal=Rheumatology|date=1997|volume=36|issue=8|pages=878-883|doi=10.1093/rheumatology/36.8.878|url=http://rheumatology.oxfordjournals.org/content/36/8/878.abstract|accessdate=30 September 2013}}</ref>. The RAQoL has 30 items with a yes and no response format<ref>{{cite journal|last=Adams|first=Jo|coauthors=Chapman, Judith; Bradley, Sarah; Ryan, Sarah Jane|title=Literacy levels required to complete routinely used patient-reported outcome measures in rheumatology|journal=Rheumatology|date=2013|volume=52|issue=3|pages=460-464|doi=10.1093/rheumatology/kes296|url=http://rheumatology.oxfordjournals.org/content/52/3/460.abstract|accessdate=30 September 2013}}</ref> and takes about six minutes to complete<ref>{{cite journal|last=de Jong|first=Z.|coauthors=van der Heijde, D.; McKenna, S.P.; Whalley, D.|title=The reliability and construct validity of the RAQoL: a rheumatoid arthritis-specific quality of life instrument.|journal=Rheumatology|date=1997|volume=36|issue=8|pages=878-883|doi=10.1093/rheumatology/36.8.878|url=http://rheumatology.oxfordjournals.org/content/36/8/878.abstract|accessdate=30 September 2013}}</ref>. The RAQoL has been used in [[clinical studies]] in order to confirm the efficacy of [[tocilizumab]]<ref>{{cite journal|last=Dougados|first=Maxime|coauthors=Kissel, Karsten; Sheeran, Tom; Tak, Paul P.; Conaghan, Philip G.; Mola, Emilio Martin; Schett, Georg; Amital, Howard; Navarro-Sarabia, Federico; Hou, Antony; Bernasconi, Corrado; Huizinga, TWJ|title=Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)|journal=Annals of Rheumatic Disease|date=2013|volume=72|issue=1|pages=43-50|doi=10.1136/annrheumdis-2011-201282|url=http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3551223/|accessdate=2 October 2013}}</ref><ref>{{cite web|title=Efficacy of tocilizumab in patients with rheumatoid arthritis|url=http://www.controlled-trials.com/ISRCTN21216199|work=Current Controlled Trials|publisher=Springer Science+Business Media.|accessdate=2 October 2013}}</ref> and [[infliximab]]<ref>{{cite journal|last=Quinn|first=Mark A.|coauthors=Conaghan, Philip G.; O'Connor, Philip J.; Karim, Zunaid; Greenstein, Adam; Brown, Andrew; Brown, Clare; Fraser, Alexander; Jarret, Stephen; Emery, Paul|title=Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twelve-month randomized, double-blind, placebo-controlled trial|journal=Arthritis & Rheumatism|date=07/01/2005|volume=52|issue=1|pages=27-35|doi=10.1002/art.20712|url=http://onlinelibrary.wiley.com/doi/10.1002/art.20712/abstract|accessdate=2 October 2013}}</ref><ref>{{cite journal|last=Bejarano|first=Victoria|coauthors=Conaghan, Philip G.; Quinn, Mark A.; Saleem, Benazir; Emery, Paul|title=Benefits 8 years after a remission induction regime with an infliximab and methotrexate combination in early rheumatoid arthritis.|journal=Rheumatology|date=2010|volume=49|issue=10|pages=1971-1974|doi=10.1093/rheumatology/keq194|url=http://rheumatology.oxfordjournals.org/content/49/10/1971.long|accessdate=2 October 2013}}</ref>.
* '''[[Pulmonary Hypertension]].'''The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) is a disease specific [[patient-reported outcome]] measure which assesses [[quality of life]] of patients with [[pulmonary hypertension]] (PH)<ref>{{cite journal|last=McKenna|first=Stephen P.|coauthors=Ratcliffe, Julie; Meads, David M.; Brazier, John E.|title=Development and validation of a preference based measure derived from the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for use in cost utility analyses.|journal=Health and Quality of Life Outcomes|date=21/08/2008|volume=6|issue=65|pages=1-8|doi=10.1186/1477-7525-6-65|url=http://www.hqlo.com/content/pdf/1477-7525-6-65.pdf|accessdate=2 October 2013}}</ref>. It was developed in 2006<ref>{{cite journal|last=McKenna|first=S.P.|coauthors=Doughty, N.; Meads, D.M.; Doward, L.C.; Pepke-Zaba, J.|title=The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR): A measure of health-related quality of life and quality of life for patients with pulmonary hypertension|journal=Quality of Life Research|date=2006|volume=15|pages=103-115|doi=10.1007/s11136-005-3513-4|url=http://download.springer.com/static/pdf/909/art%253A10.1007%252Fs11136-005-3513-4.pdf?auth66=1380882215_541823d4f6f118218ba780db9d3a5f32&ext=.pdf|accessdate=2 October 2013}}</ref> and has since been translated into fourteen different languages<ref>{{cite web|title=Measures Database|url=http://www.galen-research.com/measures-database/|work=Galen-Research.com|publisher=Galen Research|accessdate=2 October 2013}}</ref>. The CAMPHOR has been utilized in clinical trials which investigate the effects of [[treprostinil]]<ref>{{cite journal|last=Channick|first=Richard N.|coauthors=Voswinckel, Robert; Rubin, Lewis J.|title=Inhaled treprostinil: a therapeutic review|journal=Drug Design, Development and Therapy|date=24/01/2012|volume=6|pages=19-28|doi=10.2147/DDDT.S19281|url=http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3267519/|accessdate=2 October 2013}}</ref><ref>{{cite journal|last=Chen|first=Hubert|coauthors=Rosenzweig, Erika B.; Gotzkowsky, S Karl; Arneson, Carl; Nelsen, Andrew C.; Bourge, Robert C.|title=Treatment satisfaction is associated with improved quality of life in patients treated with inhaled treprostinil for pulmonary arterial hypertension|journal=Health And Quality Of Life Outcomes|date=2013|volume=11|issue=31|pages=1-8|doi=10.1186/1477-7525-11-31|url=http://www.hqlo.com/content/11/1/31|accessdate=2 October 2013}}</ref>, as well as trials which investigate [[sildenafil]]<ref>{{cite journal|last=Tay|first=Edgar L.W.|coauthors=Papaphylactou, Maria; Diller, Gerhard Paul; Alonso-Gonzalez, Rafael; Inuzuka, Ryo; Giannakoulas, Georgios; Harries, Carl; Wort, Stephen John; Swan, Lorna; Dimopoulos, Konstantinos; Gatzoulis, Michael A.|title=Quality of life and functional capacity can be improved in patients with Eisenmenger syndrome with oral sildenafil therapy|journal=International Journal of Cardiology|date=16/06/2011|volume=149|issue=3|pages=372-376|doi=10.1016/j.ijcard.2010.02.020|url=http://www.sciencedirect.com/science/article/pii/S0167527310000872#|accessdate=2 October 2013}}</ref>.<ref>{{cite journal|last=Suntharalingam|first=Jay|coauthors=Treacy, Carmen M.; Doughty, Natalie J.; Goldsmith, Kimberley; Soon, Elaine; Toshner, Mark R.; Sheares, Karen K.; Hughes, Rodney; Morrell, Nicholas W.; Pepke-Zaba, Joanna|title=Long-term Use of Sildenafil in Inoperable Chronic Thromboembolic Pulmonary Hypertension|journal=CHEST|date=2008|volume=134|issue=2|pages=229-236|doi=10.1378/chest.07-2681|url=http://journal.publications.chestnet.org/article.aspx?articleid=1085998|accessdate=2 October 2013}}</ref>



==References==
==References==

Revision as of 15:53, 8 November 2013

This page lists patient-reported quality of life surveys used in the field of medicine, pharmaceuticals, and other scientific trials. These surveys are patient-reported outcome measures, may be questionnaires or surveys, and may be used to evaluate patient satisfaction, symptoms, disease state, or psychological well-being.

List

References

  1. ^ Doward, L.C. (2003). "Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis". Annals of the Rheumatic Diseases. 62 (1): 20–26. doi:10.1136/ard.62.1.20. PMC 1754293. PMID 12480664. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  2. ^ van der Heijde, Desiree M. (17/08/2009). "Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis". Arthritis Research & Therapy. 11 (4): 1–12. doi:10.1186/ar2790. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)CS1 maint: unflagged free DOI (link)
  3. ^ Davis Jr., John C. (15/08/2007). "Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: Results from a randomized controlled study". Arthritis Care & Research. 57 (6): 1050–1057. doi:10.1002/art.22887. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
  4. ^ Marzo-Ortega, Helena (2001-09-26). "Efficacy of Etanercept in the Treatment of the Entheseal Pathology in Resistant Spondylarthropathy". Arthritis & Rheumatism. 44 (9): 2112–2117. doi:10.1002/1529-0131(200109)44:9<2112::AID-ART363>3.0.CO;2-H. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  5. ^ Marzo-Ortega, H (2003). "Bone mineral density improvement in spondyloarthropathy after treatment with etanercept". Annals of Rheumatic Diseases. 62: 1020–1021. doi:10.1136/ard.62.10.1020. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  6. ^ Meads, David M. (05/2010). "Development and validation of the Asthma Life Impact Scale (ALIS)". Respiratory Medicine. 104 (5): 633–643. doi:10.1016/j.rmed.2009.11.023. PMID 20053543. Retrieved 14 October 2013. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
  7. ^ Crawford, SR. "Further Developments of the Asthma Life Impact Scale (ALIS)" (PDF). Galen-Research.com. Galen Research. Retrieved 14 October 2013.
  8. ^ Dawson, J (1998). "Questionnaire on the perceptions of patients about total knee replacement". Journal of Bone and Joint Surgery. 80: 63–69. PMID 9460955. {{cite journal}}: |access-date= requires |url= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help); Unknown parameter |month= ignored (help)
  9. ^ Xie F, Ye H, Zhang Y, Liu X, Lei T, Li S (November 2010). "Extension from inpatients to outpatients: validity and reliability of the Oxford Knee Score in measuring health outcomes in patients with knee osteoarthritis." International Journal of Rheumatic Diseases. doi:10.1111/j.1756-185X.2010.01580.x [1]
  10. ^ a b Wirén, L.; Whalley, D; McKenna, S; Wilhelmsen, L (2000). "Application of a disease-specific, quality-of-life measure (QoL-AGHDA) in growth hormone-deficient adults and a random population sample in Sweden: Validation of the measure by Rasch analysis". Clinical Endocrinology. 52 (2): 143–52. doi:10.1046/j.1365-2265.2000.00899.x. PMID 10671940.
  11. ^ Moock, Joern; Friedrich, Nele; Völzke, Henry; Spielhagen, Christin; Nauck, Matthias; Koltowska-Häggström, Maria; Buchfelder, Michael; Wallaschofski, Henri; Kohlmann, Thomas (2011). "Prediction of improvement in quality of life (QoL-AGHDA) in adults with growth hormone deficiency by normative reference limits: Data of the German KIMS cohort". Growth Hormone & IGF Research. 21 (5): 272–8. doi:10.1016/j.ghir.2011.07.005. PMID 21865066.
  12. ^ Gilet, Hélène; Chachuat, Anne; Viala-Danten, Muriel; Auzière, Sébastien; Koltowska-Häggström, Maria (2010). "Application of the Disease-Specific Quality of Life Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA) Questionnaire in a General Population: Results from a French Panel Study". Value in Health. 13 (4): 495–500. doi:10.1111/j.1524-4733.2009.00689.x. PMID 20102556.
  13. ^ Badia, X.; Lucas, A.; Sanmartí, A.; Roset, M.; Ulied, A. (1998). "One-year follow-up of quality of life in adults with untreated growth hormone deficiency". Clinical Endocrinology. 49 (6): 765–71. doi:10.1046/j.1365-2265.1998.00634.x. PMID 10209564.
  14. ^ Mukherjee, A.; Tolhurst-Cleaver, S; Ryder, WD; Smethurst, L; Shalet, SM (2004). "The Characteristics of Quality of Life Impairment in Adult Growth Hormone (GH)-Deficient Survivors of Cancer and Their Response to GH Replacement Therapy". Journal of Clinical Endocrinology & Metabolism. 90 (3): 1542–9. doi:10.1210/jc.2004-0832. PMID 15613427.
  15. ^ Gutiérrez, Lia P.; Kołtowska-Häggström, Maria; Jönsson, Peter J.; Mattsson, Anders F.; Svensson, Dag; Westberg, Björn; Luger, Anton (2008). "Registries as a tool in evidence-based medicine: Example of KIMS (Pfizer International Metabolic Database)". Pharmacoepidemiology and Drug Safety. 17 (1): 90–102. doi:10.1002/pds.1510. PMID 17957812.
  16. ^ Patrick, Donald L. (07/2000). "Further Development and Testing of the Migraine-Specific Quality of Life (MSQOL) Measure". Headache: The Journal of Head and Face Pain. 40 (7): 550–560. doi:10.1046/j.1526-4610.2000.00086.x. Retrieved 8 October 2013. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
  17. ^ Garcia-Monco, JC (08/2007). "Impact of preventive therapy with nadolol and topiramate on the quality of life of migraine patients". Cephalalgia. 27 (8): 920–928. doi:10.1111/j.1468-2982.2007.01367.x. Retrieved 8 October 2013. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
  18. ^ Spigt, Mark (2011). "A randomized trial on the effects of regular water intake in patients with recurrent headaches". Family Practice: 1–6. doi:10.1093/fampra/cmr112. Retrieved 8 October 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  19. ^ Merelle, SYM (02/2008). "Migraine patients as trainers of their fellow patients in non-pharmacological preventive attack management: short-term effects of a randomized controlled trial". Cephalalgia. 28 (2): 127–138. doi:10.1111/j.1468-2982.2007.01472.x. Retrieved 8 October 2013. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
  20. ^ Doward, L.C. (2009). "The development of patient-reported outcome indices for multiple sclerosis (PRIMUS)". Multiple Sclerosis. 15 (9): 1092–1102. doi:10.1177/1352458509106513. Retrieved 8 November 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  21. ^ Ziemssen, T. (10/2012). "Study design and first interim results of a registry study to establish long-term safety and pharmaco-economic data on fingolimod (Gilenya®) in multiple sclerosis patients in Germany (PANGAEA)". Multiple Sclerosis. 18 (4): 222. doi:10.1177/1352458512459019. Retrieved 9 October 2013. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
  22. ^ T., van Lokven (20/10/2011). "Study design of a non-interventional registry study to establish long-term safety and pharmaco-economic data on fingolimod (Gilenya®) in multiple sclerosis patients (PANGAEA)". 5th Joint triennial congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis. Amsterdam, The Netherlands. Retrieved 09/10/2013. {{cite conference}}: Check date values in: |accessdate= and |date= (help); Unknown parameter |booktitle= ignored (|book-title= suggested) (help); Unknown parameter |coauthors= ignored (|author= suggested) (help); line feed character in |booktitle= at position 69 (help)
  23. ^ Cascione, Mark (12/02/2013). "Patient-Reported Treatment Satisfaction, Reasons for Therapy Change, and Health-Related Quality of Life at Baseline from the Trial To Evaluate Patient OutComes, Safety and Tolerability of Fingolimod". Neurology. 80 (1). Retrieved 9 October 2013. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
  24. ^ Maurer, M (15/10/2012). "Randomised multicentre trial on safety and efficacy of rivastigmine in cognitively impaired multiple sclerosis patients". Multiple Sclerosis. 19 (5): 631–638. doi:10.1177/1352458512463481. Retrieved 9 October 2013. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
  25. ^ de Jong, Z. (1997). "The reliability and construct validity of the RAQoL: a rheumatoid arthritis-specific quality of life instrument". Rheumatology. 36 (8): 878–883. doi:10.1093/rheumatology/36.8.878. Retrieved 30 September 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  26. ^ Adams, Jo (2013). "Literacy levels required to complete routinely used patient-reported outcome measures in rheumatology". Rheumatology. 52 (3): 460–464. doi:10.1093/rheumatology/kes296. Retrieved 30 September 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  27. ^ de Jong, Z. (1997). "The reliability and construct validity of the RAQoL: a rheumatoid arthritis-specific quality of life instrument". Rheumatology. 36 (8): 878–883. doi:10.1093/rheumatology/36.8.878. Retrieved 30 September 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  28. ^ Dougados, Maxime (2013). "Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)". Annals of Rheumatic Disease. 72 (1): 43–50. doi:10.1136/annrheumdis-2011-201282. Retrieved 2 October 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  29. ^ "Efficacy of tocilizumab in patients with rheumatoid arthritis". Current Controlled Trials. Springer Science+Business Media. Retrieved 2 October 2013.
  30. ^ Quinn, Mark A. (07/01/2005). "Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twelve-month randomized, double-blind, placebo-controlled trial". Arthritis & Rheumatism. 52 (1): 27–35. doi:10.1002/art.20712. Retrieved 2 October 2013. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
  31. ^ Bejarano, Victoria (2010). "Benefits 8 years after a remission induction regime with an infliximab and methotrexate combination in early rheumatoid arthritis". Rheumatology. 49 (10): 1971–1974. doi:10.1093/rheumatology/keq194. Retrieved 2 October 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  32. ^ McKenna, Stephen P. (21/08/2008). "Development and validation of a preference based measure derived from the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for use in cost utility analyses" (PDF). Health and Quality of Life Outcomes. 6 (65): 1–8. doi:10.1186/1477-7525-6-65. Retrieved 2 October 2013. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)CS1 maint: unflagged free DOI (link)
  33. ^ McKenna, S.P. (2006). "The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR): A measure of health-related quality of life and quality of life for patients with pulmonary hypertension" (PDF). Quality of Life Research. 15: 103–115. doi:10.1007/s11136-005-3513-4. Retrieved 2 October 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  34. ^ "Measures Database". Galen-Research.com. Galen Research. Retrieved 2 October 2013.
  35. ^ Channick, Richard N. (24/01/2012). "Inhaled treprostinil: a therapeutic review". Drug Design, Development and Therapy. 6: 19–28. doi:10.2147/DDDT.S19281. Retrieved 2 October 2013. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)CS1 maint: unflagged free DOI (link)
  36. ^ Chen, Hubert (2013). "Treatment satisfaction is associated with improved quality of life in patients treated with inhaled treprostinil for pulmonary arterial hypertension". Health And Quality Of Life Outcomes. 11 (31): 1–8. doi:10.1186/1477-7525-11-31. Retrieved 2 October 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)CS1 maint: unflagged free DOI (link)
  37. ^ Tay, Edgar L.W. (16/06/2011). "Quality of life and functional capacity can be improved in patients with Eisenmenger syndrome with oral sildenafil therapy". International Journal of Cardiology. 149 (3): 372–376. doi:10.1016/j.ijcard.2010.02.020. Retrieved 2 October 2013. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
  38. ^ Suntharalingam, Jay (2008). "Long-term Use of Sildenafil in Inoperable Chronic Thromboembolic Pulmonary Hypertension". CHEST. 134 (2): 229–236. doi:10.1378/chest.07-2681. Retrieved 2 October 2013. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
Retrieved from "https://en.wikipedia.org/w/index.php?title=List_of_patient-reported_quality_of_life_surveys&oldid=580768653"